To cite this paper use one of the standards below:
Introduction: Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis, transmitted by airway. According to the World Health Organization, it has a global prevalence of 10 million people.
Multiple sclerosis (MS) is a chronic inflammatory neurological disease characterized by demyelination and neuronal loss. According to the MS Atlas, in 2020, 2.8 million people suffered from this disorder. In its treatment, medications with immunosuppressive effects on the body are widely used, and related to this, patients undergoing MS treatment could be more susceptible to Latent Tuberculosis Infection (LTBI).
Objectives: This study aims to elucidate the relationship between MS and LTBI through a systematic review.
Methods: The databases, MEDLINE/PubMed, Cochrane, ScienceDirect, LILACS and SciELO were systematically reviewed from 2010 to 2020 and Google Scholar from 2015 to 2020, to detect articles eligible for the study.
Results: Fourteen (14) studies describing the relationship between MS and LTBI were included: case report (2), prevalence (2), non-systematic review (4), expert consensus (2) and case-control study (4). Most of the articles affirm that screening for LTBI should be performed before the start of the MS treatment. Screening is highly recommended in patients before starting alemtuzumab, cladribine, teriflunomide, corticosteroids, azathioprine, cyclophosphamide, and methotrexate.
Conclusion: Few articles address the association between the contagious disease and the treatment of Multiple Sclerosis. The selected articles are observational studies, which offer limited data and differ in several aspects. These divergences make it difficult to compare the results of the articles, making it impossible to accurately state whether there is a relationship between the treatment of Multiple Sclerosis and Latent Tuberculosis Infection. However, most studies recommend screening for LTBI before starting MS treatment, especially in countries with high tuberculosis rates.
With nearly 200,000 papers published, Galoá empowers scholars to share and discover cutting-edge research through our streamlined and accessible academic publishing platform.
Learn more about our products:
This proceedings is identified by a DOI , for use in citations or bibliographic references. Attention: this is not a DOI for the paper and as such cannot be used in Lattes to identify a particular work.
Check the link "How to cite" in the paper's page, to see how to properly cite the paper